FDA
No application listedNo application naming BPC-157 or BPC 157 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDABPC-157 + TB-500: blend, components and literature
A catalog item that supplies BPC-157 and TB-500 (synthetic thymosin beta 4) together in one vial from the same lot. The single compounds are listed separately.
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is BPC-157 + TB-500?
A catalog item that supplies BPC-157 and TB-500 (synthetic thymosin beta 4) together in one vial from the same lot. The single compounds are listed separately.
No formulation-level literature is listed. One 2026 rat study compared BPC-157, synthetic thymosin beta 4 and their combination in an Achilles tendon model. PubMed returns 11 records that mention every component in the title or abstract (checked 5 October 2026). This is a count of papers that name the components, not a count of studies of the combination.
Which compounds does BPC-157 + TB-500 contain?
Which studies address the combination?
[1] Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, et al.. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37:822-837.
Compared BPC-157, synthetic thymosin beta 4 (TB-500) and their combination in a rat Achilles tendon model with biomechanical and histological analyses.
What is the regulatory status of each component?
BPC-157
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names BPC as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "BPC-157". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S0The WADA 2026 Prohibited List, in force 1 January 2026 names BPC-157 under S0 (non-approved substances). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026TB-500
FDA
No application listedNo application naming thymosin beta 4 or timbetasin or thymosin beta-4 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDAEMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names thymosin beta or timbetasin as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "thymosin beta 4" or "timbetasin". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S2.3The WADA 2026 Prohibited List, in force 1 January 2026 names TB-500 under S2.3 (growth factors and growth factor modulators). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026The blend itself was not looked up as a product in the regulator databases; the component records above apply to the single compounds.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05; citations read from PubMed 2026-10-05.